Compare · CBAT vs TMO
CBAT vs TMO
Side-by-side comparison of CBAK Energy Technology Limited (CBAT) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBAT and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $256.15B, about 2861.0x CBAT ($89.5M).
- TMO has been more active in the news (9 items in the past 4 weeks vs 1 for CBAT).
- TMO has more recent analyst coverage (25 ratings vs 0 for CBAT).
- Company
- CBAK Energy Technology Limited
- Thermo Fisher Scientific Inc
- Price
- -
- -
- Market cap
- $89.5M
- $256.15B
- 1M return
- -
- +0.17%
- 1Y return
- -
- +21.89%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 9
- Recent ratings
- 0
- 25
CBAK Energy Technology Limited
CBAK Energy Technology, Inc., together with its subsidiaries, develops, manufactures, and sells lithium batteries in Mainland China, the United States, Israel, and internationally. Its products are used in various applications, including electric vehicles, such as electric cars, electric buses, and hybrid electric cars and buses; light electric vehicles that include electric bicycles, electric motors, and sight-seeing cars; and electric tools, energy storage, uninterruptible power supply, and other high power applications, as well as cordless power tools. The company was formerly known as China BAK Battery, Inc. and changed its name to CBAK Energy Technology, Inc. in January 2017. CBAK Energy Technology, Inc. was incorporated in 1999 and is based in Dalian, China.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest CBAT
- CBAK Energy Reports Approximately US$8.22 Million in Cumulative Orders from AGV Battery Pack Manufacturer
- CBAK Energy Reports Approximately US$4.76 Million in Cumulative Sales from European RV Battery Collaboration
- CBAK Energy Agrees on Battery Supply Framework with European Customer
- CBAK Energy Signs Investment Agreement for 12 GWh Sodium-Ion Battery Project in Nanjing
- CBAK Energy Reports Internal Sodium-Ion Cell Test Results and Outlines 12 GWh Capacity Plan
- CBAK Energy to Present at Noble Capital Markets’ Emerging Growth Virtual Equity Conference on October 1, 2026
- CBAK Energy Reports 9.6% Reduction in Greenhouse Gas Emissions at Dalian Facility in 2025
- CBAK Energy Highlights Completed Nanjing Phase II Ramp-Up and Accelerating Global Demand Following Investor Conference
- CBAK Energy Secures Approximately US$96 Million Battery Cell Order from Indian Customer
- CBAK Energy Expands Model 32140 Capacity at Nanjing Phase II, Advances Digital Manufacturing
Latest TMO
- President & COO Pettiti Gianluca sold $2,898,969 worth of shares (4,133 units at $701.42) as part of a pre-agreed trading plan and exercised 3,733 shares at a strike of $309.63, decreasing direct ownership by 2% to 22,816 units (SEC Form 4)
- Thermo Fisher Scientific to Participate in UBS 2026 CEO Call Series on November 19, 2026
- Thermo Fisher Scientific Authorizes $5 Billion of Share Repurchases
- Thermo Fisher Scientific Announces Quarterly Dividend
- SEC Form SCHEDULE 13G filed by Thermo Fisher Scientific Inc
- Director Sperling Scott M gifted 3,490 shares, decreasing direct ownership by 5% to 65,989 units (SEC Form 4)
- Sr. VP and Chief HR Officer Britt Lisa P. sold $1,999,960 worth of shares (2,831 units at $706.45) (SEC Form 4)
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Leadership Update
- SEC Form 10-Q filed by Thermo Fisher Scientific Inc
- SEC Form 8-K filed by Thermo Fisher Scientific Inc